Advances in machine learning, and over 18 years of academic research by myself and my team in affective computing and social signal processing have allowed us to develop software that can reliably and consistently identify signs of long term and acute illness.

Should they wish, car and truck manufacturers could easily, or with a little enhancement, incorporate the software into preexisting safety monitoring systems.

Blueskeye AI was one of two runners up in the Mental Health and Wellbeing category at the annual Digital Leaders Impact Awards at Media City in Manchester on 22 March.

The Awards celebrate digital innovations that improve people’s lives and the world around us. They are open to any individual, business, government or non-profit using digital products or services for positive social or environmental benefit.

Blueskeye AI won the Innovation Award at the annual Medilink Midlands Business Awards at the University of Birmingham on 16 March.

The Award, sponsored by intellectual property lawyers Barker Bretell, recognises the development of an innovative technology, design or process that has produced a major improvement in business performance and impacted the market.

Naheed Visram has joined BlueSkeye AI as Vice President Sales and Marketing.

The increasing use of artificial intelligence looks set to revolutionise the pharmaceutical industry over the next few years.

There are implications for drug discovery, the development of highly targeted precision medicines and the potential to identify new treatment targets and repurpose existing drugs.

But one area that could be particularly significant is the introduction of affective computing and social signal processing to clinical trials with the potential to make such trials more efficient and effective.

Blueskeye AI has been awarded £20,000 to investigate how face sensing technology can be used to obtain insights about human behaviour in the aircraft cockpit.

The research will identify the key drivers, enablers and barriers to using such technology in aircraft cockpits. It could pave the way for their adoption by the aerospace sector enhancing passenger and crew safety.

Award winning, early stage Healthtech company, BlueSkeye AI Ltd, has secured £3.4m in funding to pursue its mission to improve people’s quality of life through the use of its proprietary face and voice analysis technology. The round was led by XTX Ventures, which invested alongside Foresight Group (through The Midlands Engine Investment Fund), Praetura Ventures (through Praetura’s GMC Life Sciences Fund), the University of Nottingham and a consortium of high-net-worth individuals.

Human Behaviour Analysis company BlueSkeye AI were announced as winners in the ‘One to Watch’ category at the Midlands Business Awards 2022. The awards celebrate the excellence that life science companies across the East and West Midlands achieve at the leading edge of the healthcare and life sciences sectors.

We are excited to announce that BlueSkeye AI has been shortlisted as a finalist for the Medilink Midlands Business Awards 2022. BlueSkeye AI have been selected as a finalist for the 2022 Medilink Innovation Award category. The winners of the Awards will be announced at the Award Ceremony held in Nottingham on 27 January 2022.

BlueSkeye AI appoints Steve Cliffe to its board of directors.

BlueSkeye has deepened the deep tech expertise on its board by appointing former CEO of Ultraleap, Steve Cliffe as a Non-Executive Director and special advisor. Steve Cliffe joins BlueSkeye as the company scales and advances its ethical AI technology, partnerships and customer portfolio.

Maternal mental health awareness week is taking place this week, a campaign to raise awareness of mental health problems during and after pregnancy, to change attitudes surrounding maternal mental health and to advocate for mums to be able to access the information and support they need. During pregnancy and the postnatal period, many mothers experience heightened anxiety, feelings of isolation, judgement and guilt which are linked to pre-and postnatal depression and other mental health problems.